Anti-NGF antibodies (e.g., tanezumab) demonstrated significant efficacy in alleviating bone metastasis-related pain in Phase III clinical trials, while potentially suppressing tumor growth via blockade of the NGF-TrkA signaling axis. The gene discussed is NGF; the disease is neoplasm.